Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase 1 study.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

This extended follow-up analysis further supports SHR2554 as a therapeutic opportunity for patients with r/r PTCLs.

Keyphrases